TSLA
Tesla
-- 431.660 RGTI
Rigetti Computing
-- 17.0800 NVDA
NVIDIA
-- 137.010 PLTR
Palantir
-- 79.080 LAES
SEALSQ Corp
-- 9.080 
NEWS
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics (NASDAQ: ALRN) is presenting data from its Phase 1b clinical trial of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis. The trial's Cohort 1, evaluating low-dose LTI-03 (2.5 mg BID), showed positive trends in seven out of eight biomarkers, with three showing statistically significant improvements in collagen synthesis, inflammation, and fibrogenesis.
The company has also completed enrollment for Cohort 2, testing high-dose LTI-03 (5 mg BID), with topline data expected soon. Pre-clinical data using precision cut lung slices (PCLS) further supports LTI-03's potential effectiveness in IPF treatment. The ongoing Phase 1b trial aims to evaluate the safety and tolerability of LTI-03 in IPF patients over 14 days of treatment.
The company has also completed enrollment for Cohort 2, testing high-dose LTI-03 (5 mg BID), with topline data expected soon. Pre-clinical data using precision cut lung slices (PCLS) further supports LTI-03's potential effectiveness in IPF treatment. The ongoing Phase 1b trial aims to evaluate the safety and tolerability of LTI-03 in IPF patients over 14 days of treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment